Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The RELEVANCE trial (ClinicalTrials.gov identifier: NCT01650701) showed that lenalidomide plus rituximab (R2) provided similar efficacy to rituximab plus chemotherapy (R-chemo) in patients with advanced-stage, previously untreated follicular lymphoma (FL). We report the second interim analysis of the RELEVANCE trial after 6 years of follow-up. Patients with previously untreated grade 1-3a FL were assigned 1:1 to R2 or R-chemo, followed by rituximab maintenance. Coprimary end points were complete response (confirmed/unconfirmed) at week 120 and progression-free survival (PFS). At median follow-up of 72 months, 6-year PFS was 60% and 59% for R2 and R-chemo, respectively (hazard ratio = 1.03 [95% CI, 0.84 to 1.27]). Six-year overall survival was estimated to be 89% in both groups. Median PFS and overall survival were not reached in either group. Overall response after progression was 61% and 59%, and 5-year estimated survival rate after progression was 69% and 74% in the R2 and R-chemo groups, respectively. The transformation rate per year in the R2 and R-chemo groups was 0.68% and 0.45%, and secondary primary malignancies occurred in 11% and 13% (P = .34), respectively. No new safety signals were observed. R2 continues to demonstrate comparable, durable efficacy and safety versus R-chemo in previously untreated patients with FL and provides an acceptable chemo-free alternative.

Conflict of interest statement

Gilles Salles

Stock and Other Ownership Interests: Owkin

Honoraria: AbbVie, Bayer, Regeneron

Consulting or Advisory Role: Roche/Genentech, Janssen, Novartis, morphosys, Epizyme, Genmab, Debiopharm Group, Velosbio, BMS, BeiGene, Incyte, Miltenyi Biotec, Ipsen, AbbVie, Kite/Gilead, Loxo/Lilly, Molecular Partners, Nordic Nanovector, RAPT Therapeutics, Takeda, incyte

No other potential conflicts of interest were reported.

Figures

FIG 1.

CONSORT diagram. ITT, intent-to-treat; R2, lenalidomide plus rituximab; R-B, rituximab + bendamustine; R-chemo, rituximab plus chemotherapy; R-CHOP, rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab + cyclophosphamide, vincristine, and prednisone.

FIG 2.

PFS by IRC (A) and OS (B) in the ITT Population. HR, hazard ratio; IRC, independent review committee; ITT, intention-to-treat; OS, overall survival; PFS, progression-free survival; R2, lenalidomide plus rituximab; R-chemo, rituximab plus chemotherapy.